##  [ANVISA's Board of Directors Expands List of Radiopharmaceutical Drugs](/mandate/anvisas-board-of-directors-expands-list-of-radiopharmaceutical-drugs) 

April 2, 2026

Summary of updated rules and expanded flexibility for the registration and approval of radiopharmaceutical medicines in Brazil. Covers expansion of the eligible list for streamlined registration, acceptance of international clinical data, minimum safety and efficacy requirements, adjustments to technical dossier submissions, labeling changes, use of foreign regulatory decisions, updated pharmacovigilance and adverse event monitoring requirements, adaptation timelines, and faster regulatory pathways for advanced radiopharmaceuticals.



[Consult Now](/webform/consult%0A?url=https://preprod.freyrsolutions.com/markdownify/node/13116)



Source

[https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/diretoria-da-anvi…](https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/diretoria-da-anvisa-amplia-lista-de-medicamentos-radiofarmacos)

<https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa>

 

 

Select Mandate HA

[ANVISA](/mandate-by-ha/anvisa)

 

Select Mandate Function

[Regulatory Affairs](/mandate-by-function/regulatory-affairs)